CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 30.14×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
331.34MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9430xvs all stocks
52-Week Change
12.23%vs all stocks
Market Capitalization
331.34MUSDvs all stocks (USD)
Enterprise Value
180.70MUSDvs all stocks (USD)
Forward P/E
-5.29xvs Biotechnology peers
Price to Book (MRQ)
2.04xvs Biotechnology peers
Enterprise to EBITDA
-3.74xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-22.61%vs Biotechnology peers
Return on Equity (TTM)
-40.23%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
1.01MUSDvs all stocks (USD)
EBITDA (TTM)
-48.34MUSDvs all stocks (USD)
Net Income (TTM)
-50.96MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-35.74MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-14.96MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-53.35MUSDvs all stocks (USD)
Pre-tax Income
-48.26MUSDFY2025 · Dec 31, 2025Net Income
-48.26MUSDFY2025 · Dec 31, 2025EBIT
-53.35MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-54.66MUSDFY2025 · Dec 31, 2025Research & Development
29.79MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
23.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.72MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-48.26MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-34.22MUSDFY2025 · Dec 31, 2025Free Cash Flow
-34.23MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
139.22MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-48.26MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
60.50KUSDFY2025 · Dec 31, 2025Stock-based Compensation
15.31MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.37MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
146.83KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-104.20KUSDFY2025 · Dec 31, 2025Capital Expenditures
-13.40KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-438.62KUSDFY2025 · Dec 31, 2025Purchase of Investments
-39.09MUSDFY2025 · Dec 31, 2025Sale of Investments
41.60MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
2.49MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
107.62MUSDFY2025 · Dec 31, 2025Shares Outstanding
132.03MSharesUpdated Jul 19, 2026Float Shares
86.88MSharesUpdated Jul 19, 2026Shares Short
19.42MSharesUpdated Jul 19, 2026Short Ratio
23.29daysvs all stocks
Short % of Shares Outstanding
23.66%vs all stocks
% Held by Insiders
5.40%vs all stocks
% Held by Institutions
78.58%vs all stocks
Total Cash (MRQ)
170.37MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.00USDUpdated Jul 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
30.14xvs Biotechnology peers
Book Value per Share (MRQ)
0.9840USDUpdated Jul 19, 2026Total Assets
181.20MUSDvs all stocks (USD)
Total Current Assets
180.11MUSDFY2025 · Dec 31, 2025Total Liabilities
8.30MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.10MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
8.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
139.22MUSDFY2025 · Dec 31, 2025Other Short-term Investments
39.54MUSDFY2025 · Dec 31, 2025Accounts Payable
1.16MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.06MUSDFY2025 · Dec 31, 2025Common Stock (Book)
131.69KUSDFY2025 · Dec 31, 2025Retained Earnings
-142.68MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
172.90MUSDvs all stocks (USD)
52-Week Low
1.33USDUpdated Jul 19, 202652-Week High
2.36USDUpdated Jul 19, 202652-Week Change
12.23%vs all stocks
Beta
0.9430xvs all stocks
50-Day MA
1.83USDUpdated Jul 19, 2026200-Day MA
1.73USDUpdated Jul 19, 2026Avg 10-Day Volume
1.06MSharesUpdated Jul 19, 2026Avg 30-Day Volume
934.03KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.4400USDUpdated Jul 19, 2026Other Income / Expense
1.37MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 30.14×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 30.14Industry median: 5.64Industry P95: 23.02Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Guangji Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Organogenesis Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
King Slide Works Co., Ltd.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
Pulse Biosciences Inc.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
Gansu Engineering Consulting Group Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets